Navigation Links
Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
Date:9/20/2010

BURLINGAME, Calif., Sept. 20 /PRNewswire/ -- Epitomics, Inc. today announced that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has chosen the company to distribute a panel of LRRK2 monoclonal antibodies that were developed under an agreement between the two parties. Under a special arrangement the antibodies are being provided at low cost to the entire PD research community to help advance LRRK2 therapeutic development efforts. The antibodies will be available to Parkinson's researchers in academic/nonprofit and industry labs on a worldwide basis.

"After a successful project to develop these LRRK2 antibodies, we are very pleased that MJFF has also chosen Epitomics to now distribute these important antibodies to the research community going forward," said Guo-Liang Yu, CEO of Epitomics. "We are happy to support this important area of research and lend a hand in helping researchers develop LRRK2 based therapies."  

"LRRK2 antibodies are critical to help move Parkinson's research forward," said Mark Frasier, PhD, associate director of research programs at MJFF. "The three unique clones chosen for initial release were identified based on several months of testing by our large network of PD researchers. Epitomics has been a great partner and we are excited that they will continue to help MJFF remove barriers to developing Parkinson's therapies."

How to Obtain LRRK2 Antibodies

These antibodies can be ordered directly from Epitomics. Detailed product information can be found on Epitomics Web site at www.epitomics.com.

About LRRK2 and LRRK2 Antibodies

LRRK2 is a Parkinson's-implicated gene discovered in 2004 that is now believed to be the single greatest genetic contributor to the disease. While it is the focus of intensive research in the Parkinson's field, a major roadblock to the successful development of LRRK2-based therapies has been the lack of hi
'/>"/>

SOURCE Epitomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
2. Metamark Genetics, Inc. Announces New Chief Scientific Officer
3. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
4. Dendreon Announces Change in Board of Directors
5. Executive Mindshare Announces New Social Media Platform for Vertical Business Networks
6. DSM Biomedical Announces Continued Partnership with Spinelab
7. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
8. Stemedica Announces Completion of Clinical Stem Cell Master Bank
9. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
10. RRD Announces Move to New Corporate Headquarters
11. Huifeng Bio-Pharmaceutical Technology, Inc. Announces the Acquisition of Shangqiu Kexin Rutin Processing Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... City, Ca. (PRWEB) August 28, 2014 ... E3 rating for an alcohol-based hand sanitizer, asks food ... harvest by comparing the hand sanitizer they’re currently using ... Spray . Hand hygiene is critical to fighting cross-contamination ... environment. Best Sanitizers believes there are key criteria ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... activity (regenerative potential) of stem cells and accelerates ... MaxCyte announces today the introduction of its ... Stem Cell Summit to be held in New ... is a validated, scalable technology for customizing the ...
... Feb. 17 Human Genome Sciences, Inc. (Nasdaq: ... GSK ) has initiated a Phase 3 clinical ... of Syncria (R) (albiglutide) in the long-term treatment ... HGS will receive a $9 million milestone payment in ...
... VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced ... (NDA) with the U.S. Food and Drug Administration (FDA) ... a single agent for remission induction treatment for patients ... novo poor-risk acute myeloid leukemia (AML). The ...
Cached Biology Technology:MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 2MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 2Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 3Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes 4Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 2Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 3Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM) 4
(Date:8/29/2014)... The rise of the Tibetan plateau -- the largest ... important for both its profound effect on climate and ... in GSA Bulletin , Katharine Huntington and colleagues ... -- using modern and fossil snail shells to investigate ... Tibet. , Views range widely on the timing ...
(Date:8/28/2014)... This news release is available in German . ... fresh water fish, owes its name to a striking pattern ... cell types, black cells, reflective silvery cells, and yellow cells ... fish and arrange as a multilayered mosaic to compose the ... all three cell types have to interact to form proper ...
(Date:8/28/2014)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the Genetics Society of America,s 27th ... October 3, 2014 in Pacific Grove, California. ... entry of students, post doctorates and scientists from ... science community and to encourage the participation of ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... bumblebee species from an ecosystem and the impact is ... seeds, a new study finds. The study, to ... Academy of Sciences , focused on the interactions between ... results show how reduced competition among pollinators disrupts floral ...
... , July 26, 2013 /PRNewswire-iReach/ -- TestoMeds is ... discounts online for those seeking testosterone or progesterone ... deficiencies. (Photo: http://photos.prnewswire.com/prnh/20130726/MN54049 ) ... testosterone replacement creams – Androforte, Androfeme, and ...
... relevant information while ignoring distractions is a core brain ... "noise," we could not effectively interact with our environment. ... cellular mechanisms responsible for the effects of attention have ... in the journal Nature , researchers from Dartmouth,s ...
Cached Biology News:Bees 'betray' their flowers when pollinator species decline 2Bees 'betray' their flowers when pollinator species decline 3Bees 'betray' their flowers when pollinator species decline 4Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 2Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 3Androforte for Low T is Better Absorbed and More Economical than Androgel or Testim! 4